Short Interest in argenx SE (NASDAQ:ARGX) Expands By 11.3%

argenx SE (NASDAQ:ARGX) saw a significant growth in short interest in July. As of July 15th, there was short interest totalling 1,770,000 shares, a growth of 11.3% from the June 30th total of 1,590,000 shares. Based on an average daily volume of 315,500 shares, the days-to-cover ratio is currently 5.6 days.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Wedbush boosted their target price on argenx from $519.00 to $560.00 and gave the stock an “outperform” rating in a report on Friday. HC Wainwright boosted their target price on argenx from $504.00 to $533.00 and gave the stock a “buy” rating in a report on Friday. Stifel Nicolaus boosted their target price on argenx from $485.00 to $500.00 and gave the stock a “buy” rating in a report on Monday, June 24th. Oppenheimer raised argenx from a “market perform” rating to an “outperform” rating and set a $546.00 target price on the stock in a report on Tuesday, July 23rd. Finally, Truist Financial boosted their target price on argenx from $480.00 to $540.00 and gave the stock a “buy” rating in a report on Monday, July 22nd. Three investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $540.37.

Institutional Trading of argenx

Several hedge funds have recently added to or reduced their stakes in the business. Lindbrook Capital LLC raised its stake in argenx by 23.1% during the 1st quarter. Lindbrook Capital LLC now owns 197 shares of the company’s stock worth $78,000 after buying an additional 37 shares during the period. Wahed Invest LLC raised its stake in shares of argenx by 9.6% in the 4th quarter. Wahed Invest LLC now owns 457 shares of the company’s stock valued at $174,000 after purchasing an additional 40 shares during the period. GAMMA Investing LLC raised its stake in shares of argenx by 51.3% in the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock valued at $51,000 after purchasing an additional 40 shares during the period. Daiwa Securities Group Inc. raised its stake in shares of argenx by 2.8% in the 4th quarter. Daiwa Securities Group Inc. now owns 1,530 shares of the company’s stock valued at $582,000 after purchasing an additional 41 shares during the period. Finally, Vanguard Personalized Indexing Management LLC raised its stake in shares of argenx by 3.1% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 1,428 shares of the company’s stock valued at $543,000 after purchasing an additional 43 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Stock Performance

argenx stock traded up $8.55 during mid-day trading on Tuesday, hitting $507.60. 219,186 shares of the company’s stock were exchanged, compared to its average volume of 324,619. argenx has a fifty-two week low of $327.73 and a fifty-two week high of $532.59. The company’s 50 day simple moving average is $418.38 and its 200-day simple moving average is $395.72.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.45 EPS for the quarter, topping the consensus estimate of ($0.89) by $1.34. The business had revenue of $489.43 million for the quarter, compared to the consensus estimate of $436.66 million. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. During the same quarter last year, the business posted ($1.69) EPS. On average, research analysts predict that argenx will post -2.59 EPS for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.